Company intelligence / Profile preview

Unity Sciences

South San Francisco, California, United Statesslideshare.net ↗

Ownership: Private
Development stage: Phase 1

Overview

Positive clinical data from Phase 2 BEHOLD study in DME showed a single injection of UBX1325 led to sustained statistically significant and clinically meaningful improvement in vision. Phase 2b ASPIRE study enrollment is complete, with data expected in 2025.

Therapeutic areas: Ophthalmology
Modalities: Senolytics
Industry: Biotech

Drug pipeline

1 asset

ORM-6151

Phase 1

Indications: Acute myeloid leukemia, Myelodysplastic syndromes

Beyond the preview

Go deeper on Unity Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unity Sciences.

Explore the full profile